Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics, Alnylam, Qiagen, Digene

Premium
Rosetta Expands Research Facility, to Add 30 Employees in ‘07
 
Rosetta Genomics said this week that it has expanded its Israeli research facility and that it intends to add approximately 30 new employees by the end of the year.
 
As of Dec. 31, 2006, Rosetta had 41 full-time employees, according to a filing with the US Securities and Exchange Commission.
 
"This expansion will enable us to advance new development programs, and accommodate the large number of scientists that have joined Rosetta recently and those we expect to add in the future," Rosetta CEO Amir Avniel said in a statement.
 

 
Alnylam Licenses RNAi Patents to Asian siRNA Supplier
 
Alnylam Pharmaceuticals said this week that it has non-exclusively licensed its Kreutzer-Limmer European patent family to Japan’s Hayashi Kasei, a supplier of siRNA to Korea and Japan, to provide research products and services.
 
Specific terms of the arrangement were not disclosed.
 
“With approximately 30 licenses granted in the US, European, and Asian markets, including 14 with research product suppliers, we believe that the vast majority of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam's intellectual property," Alnylam COO Barry Greene said in a statement.
 

 
Qiagen's $1.6B Bid for Digene Passes Federal Waiting Period
 
Qiagen this week said that federal regulators have cleared its planned acquisition of Digene.
 
The company said the Hart-Scott-Rodino antitrust deadline passed without a hitch, enabling the shop to buy Digene for $1.6 billion.
 
The deal is subject to the tender of a majority of Digene's common stock on a fully diluted basis before 11:59 p.m. EST on July 20, unless the offer is extended, as well as approval by Qiagen’s shareholders, among other conditions.
 
Qiagen said it expects to close the acquisition in August or September.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.